Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ: VXRT ) tried to produce a Covid-19 vaccine that could be taken orally as a pill, but it failed. As a result, VXRT stock is probably headed down 85% to its cash per share level, or about $1.00. Sour...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Is now the time to take a look at speculative Covid-19 play Vaxart (NASDAQ: VXRT ) stock? The clinical-stage biotech name has been at work on an oral coronavirus vaccine since before Covid-19 was declared a pandemic ...
Vaxart (VXRT), a clinical-stage biotech company, has made advances in developing a multivariant oral COVID-19 vaccine candidate. However, given that the vaccine candidate is still undergoing Phase I and Phase 2 clinical trials at a time when VXRT’s peers have long ago launched their va...
In the early days of the pandemic, Vaxart (NASDAQ: VXRT) mesmerized investors after beginning development of a tablet-based, room-temperature-stable coronavirus vaccine. The stock subsequently soared to a multiyear high of $24.90 per share in February, becoming a ten-bagger over a 1...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips An oral Covid-19 vaccine is, plain and simple, a great idea. Clinical-stage biotechnology company Vaxart (NASDAQ: VXRT ) offers an alternative to inconvenient and uncomfortable injections. And so, you’d th...
Shares of vaccine expert Vaxart (NASDAQ: VXRT) have gone on a wild ride over the past 12 months as the company has released data for its coronavirus vaccine. In this video from Motley Fool Live , recorded on April 5 , Fool.com Contributors Brian Orelli and Keith Spei...
Vaxart (VXRT) has enrolled the first subject in a Phase 1b trial, VXA-NVV-104, evaluating safety and immunogenicity of oral norovirus vaccine in elderly subjects aged 55 – 80 years. The study drug will be an oral tablet administered on Days 1 and 29. “The norovirus program ...
Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine Safety and immunogenicity data to also inform oral COVID-19 vaccine program in...
Even with three COVID-19 vaccines already on the market in the U.S., the scramble to develop better vaccines is far from over. Ocugen (NASDAQ: OCGN) and Vaxart (NASDAQ: VXRT) stand out as two small companies hoping to achieve success. Vaxart's shares skyrocketed more tha...
James River Group Holdings (JRVR) -23% after stock offering and Q1 earnings release.Fastly (FSLY) -19% on Q1 earnings release.Regional Health Properties (RHE) -15%.Rocket Companies (RKT) -13% on Q1 earnings release.Etsy (ETSY) -11% on Q1 earnings releas...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...